TITLE:
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
AUTHORS:
Susan Tsai, Kathleen K. Christians, Ben George, Paul Ritch, Kiyoko Oshima, Parag Tolat, Ashley Krepline, Beth A. Erickson, Douglas B. Evans
KEYWORDS:
Pancreas Cancer, Neoadjuvant Therapy, Review
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.1,
January
21,
2016
ABSTRACT: The majority of patients with localized pancreatic cancer (PC) who
undergo surgery followed by adjuvant therapy will develop metastatic disease,
suggesting that surgery alone is not sufficient for cure and micrometastases
are present even when are not clinically detected. As such, the delivery of
early systemic therapy may be a rational alternative to a surgery-first
approach, in an effort to provide oncologic therapies which are commensurate
with the disease stage, and improve surgical selection. This review details the
rationale for a neoadjuvant approach to localized PC and provides specific
recommendations for both pretreatment staging and treatment sequencing for
patients with resectable and borderline resectable PC.